Oruka Therapeutics, Inc.

NASDAQ:ORKA

Biotechnology

Healthcare
$95.74 +0.65%

+$0.46 today

Market cap
$6.49B
Beta
-0.30
P/E (TTM)
-33.9
EPS (TTM)
-$2.11
52W Low $10.77High $91.00

Volume 0.52M

Average 1.55M

ORKA Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Oruka Therapeutics, Inc.NASDAQ: ORKA

Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026

Capital expenditures dips below year-ago levels

Q3 FY2026 capital expenditures of $83K (cash outflow) fell 16.2% year over year, behind the +33.5% change in trailing-twelve-month capital expenditures. Over 3 fiscal years it compounded at +371.0% a year.

Context

  • Capital expenditures grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -16.2% toward the trailing-twelve-month pace of +33.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$83K— QoQ
Last fiscal yearDec 2025
-$209K+10.6% YoY
LTMSep 2026
-$219K+33.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.2%——
1 year+10.6%——
3-year CAGR+371.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(209K) USD
Year-over-year change
-10.6%

Capital Expenditures vs competitors

How ORKA compares with its peers on the latest reported figures

  • ORKA's LTM Sep 2026 capital expenditures of $219K is the 6th largest of the 10 companies compared; the peer median is $334K.
  • Its year-over-year change of +33.5% is the 3rd highest of 10, against a peer median of -42.1%.
  • Over three fiscal years its annual growth of +371.0% compares with a peer median of -40.4%.
ORKA Competitors Peer median
Capital Expenditures for ORKA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XNCRXencor, Inc.LTM Jun 2026$2.47M -62.7%-58.3%2.4%
ATTOAttovia Therapeutics, Inc.FY2025$2.31M +30.5%—171.3%
CNTBConnect Biopharma Holdings LimitedFY2025$434K -42.1%-53.4%678.1%
ALMSAlumis Inc. Common StockLTM Jun 2026$401K -77.7%-35.3%5.4%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$334K +165.1%+15.3%17.5%
ORKAOruka Therapeutics, Inc.LTM Sep 2026$219K +33.5%+371.0%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$81K -99.8%-43.2%1.0%
ZURAZura Bio LimitedLTM Mar 2026$77K -34.2%-78.9%—
ANABAnaptysBio, Inc.LTM Mar 2026$69K -81.1%-37.6%0.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 +100.0%+29.8%—
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ORKA) $334K-42.1%-40.4%5.4%

Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2020
Dec 2020
FY2021
Dec 2021
FY2022
Dec 2022
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(9.74M)(19.32M)(9.93M)(83.72M)(105.43M)
Depreciation & Amortization93K91K114K27K83K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.88M(28K)(1.66M)11.59M(2.56M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.1M(411K)(783K)3.46M693K
Other Working Capital776K383K(878K)8.13M(3.25M)
Other Non-Cash Items43K497K561K14.27M19.7M
Operating Cash Flow(7.73M)(18.76M)(10.91M)(57.84M)(88.21M)
Capital Expenditures(19K)(43K)(2K)(189K)(209K)
Acquisitions (Net)00000
Purchases of Investments000(329.94M)(520.96M)
Sales of Investments0000424.42M
Other Investing Activities00000
Investing Cash Flow(19K)(43K)(2K)(330.13M)(96.75M)
Debt Repayment(408K)0000
Common Stock Issued48.86M23.09M0449.54M170.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow48.45M23.09M0449.54M170.32M
Effect of Forex Changes000(37.43M)0
Net Change in Cash40.71M4.29M(10.91M)24.14M(14.64M)
Free Cash Flow(7.74M)(18.81M)(10.91M)(58.03M)(88.42M)

Oruka Therapeutics, Inc.

NASDAQ:ORKA

Intrinsic Alpha fair value

Locked

Current Price

$95.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.